- The European Commission (EC) has granted conditional approval to Incyte Corporation INCY - MorphoSys AG's MOR Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT).
- The conditional approval is based on the results from the L-MIND study that showed the best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%.
- Incyte has exclusive commercialization rights to tafasitamab outside the U.S.
- Related content: Benzinga's Full FDA Calendar
- Price Action: MOR shares traded 1.27% higher at $14.31 premarket Friday, and Incy shares closed 0.81% lower at $75.15 on Thursday.
INCYIncyte Corp
$67.98-0.13%
Edge Rankings
Momentum83.66
Growth96.20
Quality-
Value54.71
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
